Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncorena in connection with share issue
Mandate

Vinge advises Oncorena in connection with share issue

July 30, 2025 Capital Markets and Public M&A Life Sciences & Health

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.

The issue proceeds will be used to complete the second part of the clinical study Oncorella-1, which is a phase 1/2 study of safety, tolerability, and anti-tumor efficacy of treatment with ONC175 (Oncorena’s investigational drug product under development) for patients with metastatic clear cell, or papillary renal cell carcinoma, mRCC.

The Vinge team includes Christian Lindhé, Martin Madsen Svanberg and Nathalie Wikman.

Related

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

 Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026

Vinge advises PPI Public Property Invest AB (publ) in connection with cross-border merger and listing on Nasdaq Stockholm and Euronext Oslo Børs

 Vinge has advised PPI Public Property Invest AB (publ) (“PPI”) in connection with its listing on Nasdaq Stockholm and secondary listing on Euronext Oslo Børs. The listing was carried out through a cross-border merger whereby PPI absorbed Public Property Invest ASA, whose shares were previously listed on Euronext Oslo Børs.
May 20, 2026

Vinge represents Triton in connection with the sale of Aleris

 Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.
May 18, 2026